↓ Skip to main content

Dove Medical Press

Article Metrics

Management of bone metastases in refractory prostate cancer – role of denosumab

Overview of attention for article published in Clinical Interventions in Aging, September 2012
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (55th percentile)

Mentioned by

twitter
2 tweeters
facebook
1 Facebook page
googleplus
1 Google+ user

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
83 Mendeley
Title
Management of bone metastases in refractory prostate cancer – role of denosumab
Published in
Clinical Interventions in Aging, September 2012
DOI 10.2147/cia.s27930
Pubmed ID
Authors

Channing Paller, Philips, Michael Carducci, Paller CJ, Carducci MA, Philips GK

Abstract

This article reviews the problem of bone disease in prostate cancer and the evolving role of the novel agent denosumab, a fully human monoclonal antibody that inhibits the receptor activator of nuclear factor-κB ligand, in suppressing bone resorption and offering bone protection in this disease. Prostate cancer frequently metastasizes to bone, and additionally its treatment with androgen deprivation leads to accelerated bone loss resulting in clinically relevant skeletal complications associated with disabling symptoms. Among the bone-targeting therapeutic strategies investigated for the prevention of bone complications, the potent bisphosphonate zoledronic acid has been the most widely used agent for bone protection in the past decade. Denosumab is the first among a new class of osteoclast-targeting agents to show superior efficacy in several clinical scenarios in both prostate and breast cancer, as well as in osteoporosis, but the focus of this review will be on its role in prostate cancer. The safety and efficacy of denosumab versus zoledronic acid was established in a randomized trial, demonstrating a delay in skeletal-related events in metastatic castration-resistant prostate cancer patients. This study led to the approval of denosumab in the US. The chief risks of denosumab were hypocalcemia and osteonecrosis of the jaw. Denosumab was also approved for fracture risk reduction in patients on androgen-deprivation therapy for nonmetastatic prostate cancer. Although denosumab extended bone metastasis-free survival in a Phase III trial in men with castration-resistant nonmetastatic prostate cancer to a statistically significant degree, a Food and Drug Administration committee found that the effect was not sufficiently clinically meaningful for regulatory approval, and the Food and Drug Administration issued a letter concurring with the committee's recommendation. The role of denosumab in prostate cancer will continue to evolve either as monotherapy or in combination with other bone-targeting strategies.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 2 2%
Canada 1 1%
Taiwan 1 1%
Unknown 79 95%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 18%
Researcher 14 17%
Student > Master 12 14%
Student > Ph. D. Student 11 13%
Other 7 8%
Other 20 24%
Unknown 4 5%
Readers by discipline Count As %
Medicine and Dentistry 47 57%
Agricultural and Biological Sciences 13 16%
Biochemistry, Genetics and Molecular Biology 3 4%
Psychology 3 4%
Computer Science 2 2%
Other 4 5%
Unknown 11 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 October 2016.
All research outputs
#7,001,655
of 13,219,992 outputs
Outputs from Clinical Interventions in Aging
#611
of 1,350 outputs
Outputs of similar age
#56,222
of 128,548 outputs
Outputs of similar age from Clinical Interventions in Aging
#8
of 18 outputs
Altmetric has tracked 13,219,992 research outputs across all sources so far. This one is in the 46th percentile – i.e., 46% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,350 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 128,548 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.